Named Bioactive Compounds · Compound
Gentiopicroside
Moderate Evidencecompound1 PubMed Study
Hermetica Superfood Encyclopedia
Gentiopicroside is a secoiridoid glycoside primarily extracted from Gentiana lutea root that exerts anti-inflammatory and antioxidant effects by inhibiting the NF-κB signaling pathway and suppressing pro-inflammatory mediators including COX-2, TNF-α, and IL-6. It also activates mitophagy pathways associated with cellular longevity, as demonstrated in yeast and preliminary mammalian cellular models.
Gentiopicroside is a secoiridoid glycoside naturally occurring in the roots and rhizomes of Gentiana species, particularly Gentianae Radix et Rhizoma (Gentian root), where it is one of the most abundant phytochemicals. It is extracted using standard phytochemical methods, yielding an off-white crystalline powder that is available commercially at ≥98% purity via HPLC.
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted specifically on gentiopicroside. Current research is limited to preclinical studies investigating anti-inflammatory mechanisms and cellular models.
No clinically studied dosage ranges or standardization levels have been established for gentiopicroside in humans. Consult a healthcare provider before starting any new supplement.
Gentiopicroside is a secoiridoid glycoside (C₁₆H₂₀O₉, MW 356.33 g/mol) and is not a nutritional substance per se but rather a bitter-tasting bioactive compound found primarily in plants of the Gentianaceae family. Key details: • Primary source: Gentiana lutea (yellow gentian) root, where it is the dominant bitter glycoside, typically comprising 2–6% of dried root weight; also found in Gentiana scabra, Gentiana manshurica, and Swertia species. • Chemical nature: An iridoid monoterpene glycoside consisting of an erythrocentaurin aglycone linked to a β-D-glucose moiety. The intense bitterness (bitterness value ~12,000) is characteristic of secoiridoids. • No macronutrient value (negligible calories, protein, fat, or carbohydrate contribution at pharmacologically relevant doses). • No significant vitamin or mineral content intrinsic to the compound itself. • Typical studied doses in preclinical models: 10–200 mg/kg body weight (animal studies); in vitro concentrations range from 10–500 µM. • Co-occurring bioactives in gentian root extracts include amarogentin (extremely bitter secoiridoid, ~0.02–0.05% of root), loganic acid, swertiamarin, sweroside, mangiferin (a xanthone), and isogentisin. • Bioavailability notes: Oral bioavailability in rodent models is moderate; gentiopicroside is hydrolyzed by intestinal β-glucosidases to its aglycone (erythrocentaurin), which may be the active metabolite for some biological effects. Absorption is relatively rapid (Tmax ~30–60 min in rats). First-pass hepatic metabolism is significant. Plasma half-life is relatively short (~1–3 hours in rodent models), suggesting the need for multiple daily doses to maintain plasma levels. The glucose moiety enhances aqueous solubility compared to the aglycone. • The compound is generally consumed as part of gentian root extract (used in traditional European bitters, traditional Chinese medicine formulations such as Longdan Xiegan Tang, and herbal liqueurs like Angostura bitters and Suze), rather than as an isolated nutrient.
Gentiopicroside inhibits the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, thereby downregulating transcription of COX-2 (cyclooxygenase-2), TNF-α (tumor necrosis factor-alpha), and IL-6 (interleukin-6), which collectively reduce inflammatory cascades. It also activates mitophagy—selective autophagy of damaged mitochondria—likely through PINK1/Parkin pathway modulation, which contributes to its observed lifespan-extending effects in yeast models. Additionally, gentiopicroside scavenges reactive oxygen species (ROS) and upregulates endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, reducing oxidative cellular damage.
The majority of evidence supporting gentiopicroside's effects comes from in vitro cellular models and in vivo animal studies, with robust human clinical trials largely absent as of 2024. Animal studies using rodent models of liver injury and neuroinflammation have demonstrated statistically significant reductions in inflammatory biomarkers at doses ranging from 25–100 mg/kg body weight. Yeast (Saccharomyces cerevisiae) lifespan extension studies provide mechanistic antiaging data but cannot be directly extrapolated to human outcomes. Overall, the evidence base is preliminary and promising but insufficient to establish clinical efficacy or recommended therapeutic dosages in humans.
Gentiopicroside is generally considered low-toxicity at doses used in preclinical studies, but comprehensive human safety data are lacking, making definitive conclusions difficult. Its parent plant Gentiana lutea may potentiate the effects of anticoagulant or antiplatelet drugs such as warfarin, and caution is advised for individuals on these medications. Gentiopicroside may also interact with cytochrome P450 enzymes (particularly CYP3A4), potentially altering the metabolism of co-administered pharmaceuticals. Pregnant or breastfeeding individuals should avoid supplementation due to the absence of safety data in these populations, and those with autoimmune conditions should consult a physician before use given its immunomodulatory activity.
